Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Use of such pills, which include Sanofi SA’s Ambien and other similar drugs, was significantly higher for those in their 50s as well as age 80 and older, according to the findings from the Centers for Disease Control and Prevention. Overall about 8.6 million people, or 4 percent of U.S. adults reported recently using sleep medication, CDC’s National Center for Health Statistics said in a report. But data showed higher use among middle-aged adults ages 50 to 59 and the elderly. Six percent of those ages 50 to 59 said they had taken a prescription sleep pill in the last 30 days, and 7 percent of those age 80 and older reported such use. In between, the numbers dip slightly below 6 percent for those in their 60s and 70s. In comparison, just 2 percent of those aged 20-39 said they had recently taken a sleep aid. CDC researcher Yinong Chong said people in their 50s could have trouble sleeping because of work and family stress. “It gives the picture of a sandwiched group who has family, not only children but also probably elderly parents but still you’re likely to be in the workforce, so you get squeezed at both ends in terms of family responsibility and job responsibility,” she said. Sleep may improve when people retire before potential chronic health problems kick in and begin interfering with sleep, Chong said, adding more study is needed. The data also showed that 5 percent of women surveyed said they had recently taken a sleep aid compared to about 3 percent of male respondents, according to CDC’s report. Chong said it was not clear why women were more likely to use the drugs. While previous data have tracked prescriptions dispensed for sleep aids, the CDC said its study is the first based on a survey of actual use of such drugs. Researchers for the Atlanta-based health agency’s National Center for Health Statistics questioned a sampling of adults age 20 and older about whether they had used prescription sleep aids within the last 30 days and asked participants to show interviewers the prescription medication. “You get how many people are actually using them,” Chong said in an interview, noting that prescription data could include multiple prescriptions for one patient or prescriptions that are never filled or even used. “This is actual use.”  Prescription sleep aids have become somewhat controversial because their effect can linger even after some patients wake up. The U.S. Food and Drug Administration has begun taking a closer look at sleep drugs, ordering lower-doses for Ambien and similar pills amid concerns that their active ingredient remained in patients’ blood the following morning at levels high enough to make driving and other activities dangerous. And just last month, the FDA rejected an experimental sleep drug from Merck & Co Inc, saying the proposed doses were not safe but that a lower-dose version might be acceptable. Not surprisingly, respondents to CDC’s study who said they slept five hours or less each night or those diagnosed with a sleep disorder were more likely to report using prescription aids. Additionally, more whites and people with higher levels of education also reported greater use, the agency said. Socioeconomic factors are likely behind those numbers, Chong said, since patients must be able to afford a doctor’s care and the medication. According to prescription data from IMS Health, Ambien and other versions of the drug zolpidem was ranked 15th among the most dispensed medications in the United States.
[EX A]: Use of sleeping pills highest among older Americans: CDC.

[EX Q]: According to the story, brand-name aromatase inhibitors cost between $340 and $420 a month, but the story also points out that lower-costing, generic versions are available in the U.S. It would have been useful had the story also provided cost information for the other preventive drug options, tamoxifen and raloxifene. A particular strength of this story is its presentation of data. Dr. Winer, an independent source included in the story, translates a 65% risk reduction to mean that exemestane may reduce a woman’s risk of developing breast cancer from 3% to 1%. Not only does the story provide absolute risk, but it also presents the number needed to treat. According to the study authors, 26 women would need to take exemestane for five years to prevent a single case of breast cancer. It should be noted, however, that few women in the study completed five years of therapy. Since this is being used as a preventive measure in healthy women, side effects are very important and data should have been provided. The story indicates that “slightly” more women taking exemastane experienced hot flashes, fatigue, sweating, insomnia, and joint pain, compared to those taking placebo pills. It would have been helpful to note, for example, that 40% in the exemestane group experienced a hot flash versus 32% in the placebo group. Citing older research, the story indicates that that joint pain, muscle aches, problems having sex, and vaginal dryness may be more evident with a longer duration of use. The story makes it clear that the study was a large-scale, placebo-controlled, randomized trial, which enrolled over 4500 women in North America and Europe. The women included had at least one risk factor for breast cancer. It also notes that given the significant risk reduction associated with exemestane, the study was stopped after 3 years to give women in the control arm the option of taking exemestane to prevent possible breast cancers. More information regarding participants’ characteristics, including age and race would have been helpful. This story did not engage in disease-mongering. In addition to including experts not affiliated with the exemestane study, the story also notes that the it was funded by the Canadian Cancer Society, the Avon Foundation, and Pfizer. In addition, the writer points out that the study lead and a few other authors have received speaking fees from Pfizer and other pharmaceutical companies that make cancer drugs. This story compares the benefits and harms of exemestane with tamoxifen; however, a mention of how these compare with raloxifene, would have been useful. The availability of aromatase inhibitors is not in question. It’s clear from the story that aromatase inhibitors are currently used to prevent breast cancer recurrences. It’s also clear that this is the first study evaluating its utility for preventing the first instance of breast cancer in healthy women with a higher risk of developing the disease. The story does not appear to be based on the press release.
[EX A]: Hormone-blocking drug reduces breast cancer risk

[EX Q]: Poor training, a lack of coordination and an overstretched military are also factors, but a new 76-point plan lays out ways to improve this, Colonel John Bradley, chief of psychiatry at Walter Reed Army Hospital in Washington, told a conference. Bradley said a team of experts spent a year interviewing troops who had attempted suicide, family members and others for the report and plan, presented last month to Defense Secretary Robert Gates, who is due to report to Congress in 90 days. “They tell us again and again that we are failing,” Bradley told a symposium on military medicine sponsored by the Uniformed Services University of the Health Sciences and the Henry M. Jackson Foundation. Each branch of the services — the Army, Air Force, Navy and Marines — rushed to create a suicide prevention program, but there was no coordination. The report recommends that the defense secretary’s office take over coordination of suicide prevention efforts. On-the-ground prevention training often failed because those running the sessions did not understand their importance, Bradley said. “They are mocked and they are probably harmful,” he said. According to the report, available here 1,100 servicemen and women committed suicide in 2005 to 2009 -- one suicide every day and a half. The Army's suicide rate doubled in that time. About 1.9 million U.S. service men and women have been deployed in Iraq and Afghanistan. “We have done all the right things but despite all the things we have done, suicide rates have risen, particularly in the Marines and Army,” said Colonel Charles Hoge of Walter Reed. “A large percentage of our servicemen, our veterans, do not come in to get help,” he added. “It is not just the perception that they will be treated differently or somehow that it will affect their career, but it is also distrust in the system and distrust that mental health professionals can help them,” Hoge added. “They don’t trust us. They believe we speak with forked tongues,” Bradley said. Most of the suicides are among young, white males, the experts said. “Marines are young, they are confident, they are aggressive,” said Lieutenant General Richard Zimmer of the U.S. Marine Corps. “They are the last ones to raise their hand and say they have a problem.”   And troops who seek mental health services can lose their security clearances, their weapons and can be taken away from duties vital to their careers, Hoge and Bradley said. When they return home from war, the skills that kept them alive under fire make them dysfunctional in civilian society, Hoge said. “There are messages that the warrior gets when they back here that they are crazy,” he said. In addition, all the services are overstretched, the report said. “The force is out of balance,” Bradley said. “The force is fatigued. Anyone who doesn’t believe that has their eyes closed.”   Hoge said physical demands can also affect the mind. Troops often operate on just 3 or 4 hours a sleep a night for extended periods. “They often have pain, chronic pain,” he said. “They have gone through all these events, including concussions. It is clear there are physical changes that happen.”   Bradley said the report calls for skills-based training for commanders, troops and their families.
[EX A]:
Military suicide prevention efforts fail: report.